Brought to you by 
Illumina nets $390mm in placement of convertible debt
28 Feb 2007
Executive Summary
Illumina (tools for genetic analysis) netted $390.3mm through the placement of $400mm principal amount (including the overallotment) of 0.625% convertible senior notes due 2014 to Goldman Sachs and Deutsche Bank. The conversion price for the notes is $43.66 per share. (Illumina's market average was $35.98 at the time of the placement.)
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
-
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Antisense, Oligonucleotides
- Nanotechnology, Chips, etc.
- Pharmacogenetics-Pharmacogenomics
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Financing
- Convertible Debt
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Illumina nets $390mm in placement of convertible debt
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice